MENU

Yanis Boumber, MD, PhD

Yanis Boumber, MD, PhD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Treatment Focus

Thoracic Oncology (chemotherapy, targeted therapy and immunotherapy)

Research Program

Language(s) Other than English

Russian

Treatment Philosophy

I chose Fox Chase as a place to be due to its excellent reputation in both high quality patient care and innovative cancer research.

Fascination with biology research and rapid advances in cancer medicine has brought me to the field of medical oncology. I love my work as a physician, enjoy taking care of cancer patients and their families, and have a great interest in lung cancer. Each patient is unique, and it is of great importance to develop individualized treatment plans designed to target specific tumors. I do my very best to take care of complicated cancer patients.

Fox Chase offered me a unique opportunity to work both in the clinic and in the lab.  I am interested in studying basic research, as well as in translating laboratory discoveries using novel targeted agents in lung cancer to the clinic by conducting clinical trials, and above all to deliver the best possible patient care.  

Follow on Twitter: @yanisboumbermd

Education, Training & Credentials

Educational Background

  • Fellowship, Hematology/Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX,  2010-2013
  • Residency, Good Samaritan Hospital, affiliated with Johns Hopkins University, Baltimore, MD, 2007-2010
  • Postdoctoral Fellowship, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2005-2007
  • PhD, Cancer Biology and Molecular Biology, University of Texas M.D. Anderson Cancer Center and Graduate School of Biomedical Sciences, Houston, TX, 2005
  • MD, Rostov State Medical University, Rostov-on-Don, Russia, 1999

Certifications

  • Board Certified, Medical Oncology, 2013
  • ABIM- Medical Oncology, 2013
  • ABIM- Internal Medicine, 2010
  • ECFMG Certification, 2007

Memberships

  • American Association of Cancer Research
  • American Society of Clinical Oncology
  • International Association for the Study of Lung Cancer
  • ECOG
  • University of Texas GSBS Alumni Association   

Honors & Awards

  • ECOG-ACRIN Young Investigator Award Nominee, 2014
  • Celgene Future Leaders in Hematology Award, 2012
  • ASCO Young Investigator Award,  2012
  • American Society of Hematology Merit Award, 2011
  • Good Samaritan Hospital, Baltimore, MD, Outstanding Performance in Ambulatory Medicine Award, 2010
Research Profile

Research Program

Research Interests

RNA binding proteins, cancer cell signaling and novel therapeutics in lung cancer.

  • Musashi-2 role in lung cancer
  • Signaling pathways regulated by Musashi-2 in lung cancer
  • Novel therapeutic approaches to target lung cancer
  • Epigenetics in lung cancer

Lab Overview

The Musashi-2 project originated in the analysis of highly metastatic versus less metastatic lung cancers emerging in a KRAS/p53 mutated mouse model of lung cancer.  MSI2 is an RNA-binding protein that regulates mRNA translation, and has previously been shown to have dysregulated function in leukemias. We identified MSI2 upregulation as common in the more metastatic cells derived from mice tumors and patient samples, and showed that loss of MSI2 decreased invasion and metastasis. MSI2 upregulates TGFβ and SMAD3 and suppresses claudins expression in lung cancer which contributes to metastatic lung cancer phenotype (Kudinov et al, PNAS, 2016). We hope these studies of MSI2 will eventually lead us to improved treatment strategies of this difficult cancer.

We have also for the first time evaluated STA-12-8666, a promising new HSP90-targeted therapy for small cell lung cancer (Gaponova et al, Clinical Cancer Research, 2016). We are planning to expand our investigations of novel compounds to treat lung cancer, in collaboration with Golemis lab.

Our current interests involve investigation of signaling pathways and biological processes controlled by MSI2 in lung cancer and developing novel therapeutic approaches to target MSI2 in lung cancer.

People

Alexander Kudinov, MD

Visiting Scientist

Room: W406
215-728-3885
Publications

Selected Publications

Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016 Jun 6; PubMed PMID: 27274057

Bansal P, Osman D, Gan GN, Simon GR and Boumber, Y. Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Frontiers in Oncology, 2016. doi: 10.3389/fonc.2016.00112. PMID: 27200298

Gaponova AV, Nikonova AS et al, Boumber Y and Golemis EA. A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC). Clinical Cancer Research, 2016; PMID: 27267850

Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D, Donahoe PK, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, Golemis EA. Anti-Müllerian hormone signaling regulates epithelial plasticity and chemoresistance in lung cancer. Cell Rep. 2016 Jul 6. pii: S2211-1247 (16)30797-5. PMID: 27396341

Gaponova AV, Nikonova A, Deneka AY, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Shin Ogawa L, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA. A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC). Clin Cancer Res. 2016 Jun 7; PubMed PMID: 27267850

Shih J, Bashir B, Gustafson KS, Andrake M, Dunbrack RL, Goldstein LJ, Boumber Y. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. J Natl Compr Canc Netw. 2015 Aug;13(8):947-52. PubMed PMID: 26285240; PubMed Central PMCID: PMC4763101

Boumber Y, Issa JP. Epigenetics in cancer: what’s the future? Oncology, 2011 Mar;25(3):220-6, 228. Pubmed PMID: 21548464.

Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, Estécio MR, Ahmed S, Issa JP. An Sp1/Sp3 binding polymorphism confers methylation protection. PLoS Genet. 2008 Aug 22;4(8):e1000162. PubMed PMID: 18725933; PubMed Central PMCID: PMC2515197

Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007 Mar 1;67(5):1997-2005. PubMed PMID: 17332327.

Additional Publications

My NCBI